These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22664127)

  • 21. Design and synthesis of β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of β-amyloid peptides.
    Swahn BM; Kolmodin K; Karlström S; von Berg S; Söderman P; Holenz J; Berg S; Lindström J; Sundström M; Turek D; Kihlström J; Slivo C; Andersson L; Pyring D; Rotticci D; Ohberg L; Kers A; Bogar K; von Kieseritzky F; Bergh M; Olsson LL; Janson J; Eketjäll S; Georgievska B; Jeppsson F; Fälting J
    J Med Chem; 2012 Nov; 55(21):9346-61. PubMed ID: 22924815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.
    Finlay HJ; Jiang J; Caringal Y; Kover A; Conder ML; Xing D; Levesque P; Harper T; Hsueh MM; Atwal K; Blanar M; Wexler R; Lloyd J
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1743-7. PubMed ID: 23414837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists.
    Venkatesan G; Paira P; Cheong SL; Federico S; Klotz KN; Spalluto G; Pastorin G
    Eur J Med Chem; 2015 Mar; 92():784-98. PubMed ID: 25633494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.
    Tye H; Mueller SG; Prestle J; Scheuerer S; Schindler M; Nosse B; Prevost N; Brown CJ; Heifetz A; Moeller C; Pedret-Dunn A; Whittaker M
    Bioorg Med Chem Lett; 2011 Jan; 21(1):34-7. PubMed ID: 21146986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Solution phase parallel synthesis of substituted 3-phenylsulfonyl-[1,2,3]triazolo[1,5-a]quinazolines: selective serotonin 5-HT(6) receptor antagonists.
    Ivachtchenko AV; Golovina ES; Kadieva MG; Koryakova AG; Kovalenko SM; Mitkin OD; Okun IM; Ravnyeyko IM; Tkachenko SE; Zaremba OV
    J Comb Chem; 2010 Jul; 12(4):445-52. PubMed ID: 20349953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis of substituted diphenyl sulfones and their structure-activity relationship with the antagonism of 5-НТ6 receptors.
    Ivachtchenko A; Golovina E; Kadieva M; Mitkin O; Tkachenko S; Okun I
    Bioorg Med Chem; 2013 Aug; 21(15):4614-27. PubMed ID: 23787290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrazolo[3,4-d]pyrimidinophanes: convenient synthesis of a new class of cyclophane and X-ray structure of the first representative.
    Avasthi K; Ansari A; Tewari AK; Kant R; Maulik PR
    Org Lett; 2009 Nov; 11(22):5290-3. PubMed ID: 19905030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW; Bridges AJ; Fry DW; Rubin JR; Denny WA
    J Med Chem; 1997 Jun; 40(12):1820-6. PubMed ID: 9191958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A stacked pyrazolo[3,4-d]pyrimidine-based flexible molecule: the effect on stacking of an ethyl group in comparison with a methyl group.
    Avasthi K; Aswal S; Maulik PR
    Acta Crystallogr C; 2001 Nov; 57(Pt 11):1324-5. PubMed ID: 11706263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
    Rewcastle GW; Palmer BD; Thompson AM; Bridges AJ; Cody DR; Zhou H; Fry DW; McMichael A; Denny WA
    J Med Chem; 1996 Apr; 39(9):1823-35. PubMed ID: 8627606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
    Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
    Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore elucidation for a new series of 2-aryl-pyrazolo-triazolo-pyrimidines as potent human A3 adenosine receptor antagonists.
    Cheong SL; Federico S; Venkatesan G; Paira P; Shao YM; Spalluto G; Yap CW; Pastorin G
    Bioorg Med Chem Lett; 2011 May; 21(10):2898-905. PubMed ID: 21511471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and pharmacological evaluation of piperidin-4-yl amino aryl sulfonamides: novel, potent, selective, orally active, and brain penetrant 5-HT₆ receptor antagonists.
    Nirogi R; Shinde A; Daulatabad A; Kambhampati R; Gudla P; Shaik M; Gampa M; Balasubramaniam S; Gangadasari P; Reballi V; Badange R; Bojja K; Subramanian R; Bhyrapuneni G; Muddana N; Jayarajan P
    J Med Chem; 2012 Nov; 55(21):9255-69. PubMed ID: 23006002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
    Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
    J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
    Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and isomerization of some novel pyrazolopyrimidine and pyrazolotriazolopyrimidine derivatives.
    Rashad AE; Shamroukh AH; Abdel-Megeid RE; Ali HS
    Molecules; 2014 Apr; 19(5):5459-69. PubMed ID: 24776812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and BZR affinity of pyrazolo[1,5-a]pyrimidine derivatives. Part 1: study of the structural features for BZR recognition.
    Selleri S; Bruni F; Costagli C; Costanzo A; Guerrini G; Ciciani G; Costa B; Martini C
    Bioorg Med Chem; 1999 Dec; 7(12):2705-11. PubMed ID: 10658575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anhydrous versus hydrated N4-substituted 1H-pyrazolo[3,4-d]pyrimidine-4,6-diamines: hydrogen bonding in two and three dimensions.
    Trilleras J; Quiroga J; Cobo J; Marchal A; Nogueras M; Low JN; Glidewell C
    Acta Crystallogr B; 2008 Oct; 64(Pt 5):610-22. PubMed ID: 18799849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.